Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySirukumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Sirukumab
- Accession Number
- DB11803
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- Categories
- UNII
- 640443FU93
- CAS number
- 1194585-53-9
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Sirukumab. Abituzumab The risk or severity of adverse effects can be increased when Sirukumab is combined with Abituzumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Sirukumab. Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Sirukumab. Aducanumab The risk or severity of adverse effects can be increased when Sirukumab is combined with Aducanumab. Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Sirukumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Sirukumab. Amatuximab The risk or severity of adverse effects can be increased when Sirukumab is combined with Amatuximab. AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Sirukumab. - Food Interactions
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Healthy Volunteers 1 1 Completed Basic Science Rheumatoid Arthritis 1 2 Completed Treatment Major Depressive Disorder (MDD) 1 2 Completed Treatment Rheumatoid Arthritis 1 2 Withdrawn Treatment Asthma Bronchial 1 3 Completed Treatment Rheumatoid Arthritis 5 3 Terminated Treatment Giant Cells Arteritis 1 3 Withdrawn Treatment Polymyalgia Rheumatica 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Drug created on October 20, 2016 14:49 / Updated on November 02, 2018 07:15